Relay Therapeutics

company in Cambridge, United States

RLAY Nasdaq SEC CIK 1812364
Follow Relay Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0
Net income −$81.7M −10.2% vs same quarter last year
EPS, diluted −$0.37 +14% vs same quarter last year
Operating cash flow −$63.9M −2.9% vs same quarter last year
Revenue by quarter
$0
$7.7M
$677K
$0
$7M
$3M
$350K
$0
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
  • Revenue
  • Net income
−$400M−$200M$0$200MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$15.4M−$276.5M
FY24$10M−$337.7M
FY23$25.5M−$342M
FY22$1.4M−$290.5M
FY21$3M−$363.9M
FY20$82.7M−$52.4M
FY19-−$75.3M
FY18--
MarginsShare of revenue
  • Operating margin
  • Net margin
−30000%−20000%−10000%0%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−1971.6%−1800.6%
FY24−3722.1%−3374.7%
FY23−1460.1%−1338.7%
FY22−21670.9%−21036.1%
FY21−12040.2%−12012.9%
FY20−67.5%−63.4%
FY19--
FY18--
Free cash flowOperating cash flow minus capital expenditure
−$400M−$300M−$200M−$100M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$235.9M
FY24−$251.1M
FY23−$304.4M
FY22−$238.6M
FY21−$77.9M
FY20−$104.4M
FY19−$74.1M
FY18-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Relay Therapeutics
  • Healthcare median
−30000%−20000%−10000%0%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRelay TherapeuticsHealthcare median
FY25−1800.6%−30.6%
FY24−3374.7%−47%
FY23−1338.7%−58%
FY22−21036.1%−80.4%
FY21−12012.9%−71.8%
FY20−63.4%−62.2%
FY19-−46.2%
FY18-−49.6%